Denali Therapeutics (DNLI) Cash & Equivalents (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Cash & Equivalents data on file, last reported at $387.6 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $387.6 million, up 580.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $387.6 million (up 580.68% YoY), and the FY2025 annual result was $205.3 million, up 17.36% from the prior year.
• Cash & Equivalents grew to $387.6 million in Q1 2026 per DNLI's latest filing, from $205.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $387.6 million in Q1 2026 and troughed at $56.9 million in Q1 2025.
• A 5-year average of $138.5 million and a median of $127.1 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents plunged 75.89% in 2022, then jumped 580.68% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $218.0 million in 2022, then tumbled by 41.71% to $127.1 million in 2023, then jumped by 37.65% to $175.0 million in 2024, then grew by 17.36% to $205.3 million in 2025, then soared by 88.79% to $387.6 million in 2026.
• Business Quant data shows DNLI's Cash & Equivalents at $387.6 million in Q1 2026, $205.3 million in Q4 2025, and $91.0 million in Q3 2025.